Twice-Daily Dosing of Dolutegravir in Infants on Rifampicin Treatment: A Pharmacokinetic Substudy of the EMPIRICAL Trial

Background
This study evaluated the pharmacokinetics of dolutegravir in HIV-infected infants receiving twice-daily (BID) dolutegravir with rifampicin-based tuberculosis (TB) treatment compared to once-daily (OD) dolutegravir without rifampicin.

Conclusions
Dolutegravir BID with rifampicin provided adequate drug exposure, supporting its use for infants with HIV-TB coinfection. HIV viral suppression rates were high, with no significant safety concerns reported.